ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026
Regulatory T cells attenuate astrogliosis via IL-10/STAT3/PKC/vimentin signaling and promote neurological recovery after spinal cord injury.
Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Characterization of a distinct form of vimentin in the neurodegenerative brain.Acta neuropathologica communications · 2026Article
- Regulatory T cells in intracerebral hemorrhage: mechanisms of immunomodulation and therapeutic potential.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) triggers reactive astrogliosis, leading to the formation of an astrocyte scar around the lesion. Regulatory T cells (Tregs), a subset of immune cells, infiltrate the peri-lesional area through the compromised blood-spinal cord barrier. However, the regulatory role of Tregs in post-SCI astrogliosis and its underlying mechanisms remain unclear. Here, we demonstrated that Tregs attenuate astrogliosis and promote neurological recovery after SCI. Treg-depleted mice exhibited exacerbated astrocyte activation, increased chondroitin sulfate proteoglycan (CSPG) deposition, and impaired axonal remodeling post-SCI. Through transcriptomic profiling, we identified vimentin (Vim) as a key gene in astrocytes upregulated by Treg depletion following SCI. In vitro Treg co-culture attenuated oxygen-glucose deprivation/reoxygenation (OGD/R)-induced astrocyte activation, CSPG secretion, and vimentin high expression. Virus-mediated vimentin knockdown recapitulated Treg-mediated suppression of in vitro astrocyte activation and in vivo astrogliosis, and further ameliorated Treg depletion-induced pathological outcomes. In vitro pharmacological studies in astrocytes reveal that vimentin expression is modulated by exogenous IL-10 signaling and downstream STAT3/PKC phosphorylation. These findings demonstrate that Tregs attenuate post-SCI astrogliosis via the IL-10/STAT3/PKC/vimentin signaling axis, thereby facilitating axonal remodeling and promoting neurological recovery. Our study provides novel insights into the Treg-mediated neuroimmune repair mechanisms and establishes promising therapeutic targets for SCI treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.